A Form 4 filed on November 17, 2026 reports that Marvin Slosman, CEO and President of InspireMD, Inc. (NASDAQ:NSPR), purchased 46,154 shares of common stock and 34,616 Series L common stock warrants on November 13, 2026 through the company's underwritten public offering.

Key Highlights

  • Purchase transaction: Marvin Slosman acquired 46,154 shares of common stock on November 13, 2026 at a price of $0.65 per share.
  • Public offering context: According to the filing, the shares were purchased "in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants."
  • Warrant acquisition: Slosman also acquired 34,616 Series L common stock warrants on November 13, 2026 at a price of $0.00.
  • Warrant terms: The Series L warrants are immediately exercisable at $0.65 per share and expire on November 16, 2027.
  • Post-transaction ownership: Following the reported transaction, Slosman directly beneficially owns 3,602,812 shares of common stock and 34,616 Series L warrants.
  • Roles: Slosman is identified in the filing as both a Director and Officer (CEO and President) of InspireMD, Inc.

Slosman's November 2026 Open-Market Purchase in InspireMD's Public Offering

According to the Form 4 filed with the SEC on November 17, 2026, Marvin Slosman, CEO and President of InspireMD, Inc. (NASDAQ:NSPR), participated in the company's underwritten public offering on November 13, 2026. The filing records a purchase (transaction code "P") of 46,154 shares of common stock at $0.65 per share. The filing states this price represents "a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants."

In addition to the common stock purchase, the filing reports that Slosman acquired 34,616 Series L common stock warrants on the same date, also coded as a purchase. The warrants were acquired at $0.00 and are described as "immediately exercisable at an exercise price of $0.65 per share," with an expiration date of November 16, 2027. The warrant exercise period begins November 16, 2026, per the filing.

Following these transactions, the filing reports that Slosman directly and beneficially owns 3,602,812 shares of common stock and 34,616 Series L warrants. The Form 4 was signed by Michael Lawless as Attorney-in-Fact for Marvin Slosman and filed on November 17, 2026.

What Was Disclosed

InspireMD CEO and President Marvin Slosman reported the purchase of 46,154 common shares and 34,616 Series L warrants in the company's underwritten public offering on November 13, 2026, bringing his direct beneficial ownership to 3,602,812 shares.